Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Why Are Clinical Trials Not Typically a Care Option?

  • Broadcast in Science
Pharma Talk Radio

Pharma Talk Radio

×  

Follow This Show

If you liked this show, you should follow Pharma Talk Radio.
h:548881
s:11186697
archived

Murray Abramson, MD, VP Clinical Operations, Biogen and Jeff James, CEO, Wilmington Health, discuss the blockers and enablers to making clinical research a care option. Discuss includes:

  • What are the blockers or conflicts (laws, culture, behaviors, etc) that prevent clinical research from becoming a care option?
  • What is the difference between a movement and an initiative - how should be think about clinical research as a care option? Benefits?
  • What are the enablers or requirements to incorporate clinical research into care options for the patient?
  • How to pave a path for possibility
  • Update on data to support how trials can be a care option

This discussion was held at the Clinical Research as a Care Option (CRAACO) meeting held April 11, 2018 in Cambridge, MA.

The 2019 CRAACO meeting will take place April 29-30 in Raleigh-Durham, NC. Find out more here.

Comments